SEC Form 4Coverage since Jun 17, 2026
$NSRX insider trading
Over the last 12 months, Nasus Pharma insiders reported 1 buy totaling $20K and no sales across SEC Form 4 filings.
- Bought · 12m
- $20K 1 event
- Sold · 12m
- — 0 events
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $NSRX · 12Mvia TradingView
Top insiders · 12m
Teleman Dan BenjaminChief Executive Officer1× · $20K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Teleman Dan BenjaminChief Executive Officer · O·D | ▲ Buy | 6,550 | $3.1 | $20K | +4.2% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NSRX feed.